{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:00:53Z","timestamp":1790168453922,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":84,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Everolimus (EVR), which is widely used in heart transplant recipients, has been associated with drug-induced lung injury. Although EVR-associated lung injury has been reported in patients with malignancies and recipients of other solid organ transplants, its incidence and risk factors in heart transplant recipients remain unclear. Krebs von den Lungen-6 (KL-6) is a serum biomarker widely used in the assessment of interstitial lung diseases and may reflect pulmonary involvement, including drug-induced lung injury. This study aimed to determine the incidence and risk factors for KL-6 elevation after EVR administration in heart transplant recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective observational study included patients who received a heart transplant at the University of Tokyo Hospital from June 2006 to April 2021. The patients were categorized into two groups: those who received EVR after heart transplantation (EVR group) and those who did not (non-EVR group). Multivariable logistic regression analysis was performed in the EVR group to identify independent risk factors for KL-6 elevation (defined as a peak level\u2009\u2265\u2009500\u2009U\/mL). Receiver operating characteristic (ROC) analysis was used to determine optimal cutoff values, and a composite risk score was constructed. Event-free survival was evaluated using the Kaplan\u2013Meier method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seventy-three patients were included (58 in the EVR group and 15 in the non-EVR group). Peak serum KL-6 levels were significantly higher in the EVR group than in the non-EVR group (320 [235\u2013509] vs. 157 [127\u2013263] U\/mL,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). KL-6 elevation occurred in 27.6% and 6.7% of patients in the EVR and non-EVR groups, respectively. Within the EVR group, higher baseline KL-6 levels and lower eGFR were independently associated with KL-6 elevation. ROC analysis identified cutoff values of baseline KL-6\u2009&gt;\u2009268\u2009U\/mL and eGFR\u2009&lt;\u200960\u2009mL\/min\/1.73\u2009m\n                      <jats:sup>2<\/jats:sup>\n                      . Higher composite risk scores were associated with a greater incidence of KL-6 elevation, and patients with both risk factors experienced earlier KL-6 elevation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>EVR administration was associated with KL-6 elevation in heart transplant recipients. Elevated baseline KL-6 levels and impaired renal function before EVR initiation were independent predictors of KL-6 elevation. Assessment of these parameters may help earlier detection of EVR-associated KL-6 elevation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40780-026-00603-0","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T06:15:36Z","timestamp":1782972936000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum KL-6 and eGFR predict everolimus-associated KL-6 elevation in heart transplant recipients: a retrospective observational study"],"prefix":"10.1186","volume":"12","author":[{"given":"Yuhei","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyohito","family":"Oriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehito","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Amiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie","family":"Bujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiko","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tappei","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"issue":"8","key":"603_CR1","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1111\/ajt.12809","volume":"14","author":"AK Andreassen","year":"2014","unstructured":"Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Radegran G, Gude E, et al. Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial. Am J Transpl. 2014;14(8):1828\u201338. Available from: doi: https:\/\/doi.org\/10.1111\/ajt.12809.","journal-title":"Am J Transpl"},{"issue":"7","key":"603_CR2","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/tri.12783","volume":"29","author":"L Gullestad","year":"2016","unstructured":"Gullestad L, Eiskjaer H, Gustafsson F, Riise GC, Karason K, Dellgren G, et al. Long-term outcomes of thoracic transplant recipients following conversion to everolimus with reduced calcineurin inhibitor in a multicenter, open-label, randomized trial. Transpl Int. 2016;29(7):819\u201329. Available from: doi: https:\/\/doi.org\/10.1111\/tri.12783.","journal-title":"Transpl Int"},{"key":"603_CR3","doi-asserted-by":"publisher","unstructured":"Velleca A, Shullo MA, Dhital K, Azeka E, Colvin M, DePasquale E, et al. The International Society for heart and lung transplantation (ISHLT) guidelines for the care of heart transplant recipients. The J Heart Lung Transpl. 2023;42(5):e1\u2013141. Available from: doi: https:\/\/doi.org\/10.1016\/j.healun.2022.10.015.","DOI":"10.1016\/j.healun.2022.10.015"},{"issue":"5","key":"603_CR4","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/ajt.12181","volume":"13","author":"HJ Eisen","year":"2013","unstructured":"Eisen HJ, Kobashigawa J, Starling RC, Pauly DF, Kfoury A, Ross H, et al. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. Am J Transpl. 2013;13(5):1203\u201316. Available from: doi: https:\/\/doi.org\/10.1111\/ajt.12181.","journal-title":"Am J Transpl"},{"issue":"5","key":"603_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.jchf.2013.07.002","volume":"1","author":"JA Kobashigawa","year":"2013","unstructured":"Kobashigawa JA, Pauly DF, Starling RC, Eisen H, Ross H, Wang SS, et al. Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the everolimus versus mycophenolate mofetil randomized, multicenter trial. JACC Heart Fail. 2013;1(5):389\u201399. Available from: doi: https:\/\/doi.org\/10.1016\/j.jchf.2013.07.002.","journal-title":"JACC Heart Fail"},{"key":"603_CR6","doi-asserted-by":"publisher","unstructured":"Arora S, Andreassen AK, Karason K, Gustafsson F, Eiskj\u00e6r H, B\u00f8tker HE, et al. Effect of everolimus initiation and calcineurin inhibitor elimination on Cardiac allograft vasculopathy in De novo heart transplant recipients. Circ: Heart Fail. 2018;11(9):e004050. Available from: doi: https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.117.004050.","DOI":"10.1161\/CIRCHEARTFAILURE.117.004050"},{"key":"603_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijcard.2018.03.111","volume":"265","author":"DL Jennings","year":"2018","unstructured":"Jennings DL, Lange N, Shullo M, Latif F, Restaino S, Topkara VK, et al. Outcomes associated with mammalian target of rapamycin (mTOR) inhibitors in heart transplant recipients: a meta-analysis. Int J Cardiol. 2018;265:71\u201376. Available from: doi: https:\/\/doi.org\/10.1016\/j.ijcard.2018.03.111.","journal-title":"Int J Cardiol"},{"issue":"3","key":"603_CR8","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1164\/rccm.200911-1720OC","volume":"182","author":"DA White","year":"2010","unstructured":"White DA, Camus P, Endo M, Escudier B, Calvo E, Akaza H, et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med. 2010;182(3):396\u2013403. Available from: doi: https:\/\/doi.org\/10.1164\/rccm.200911-1720OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"603_CR9","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1002\/ijc.29887","volume":"138","author":"AECAB Willemsen","year":"2016","unstructured":"Willemsen AECAB, Grutters JC, Gerritsen WR, van Erp NP, van Herpen CML, Tol J. mTOR inhibitor-induced interstitial lung disease in cancer patients: comprehensive review and a practical management algorithm. Intl J Cancer. 2016;138(10):2312\u201321. Available from: doi: https:\/\/doi.org\/10.1002\/ijc.29887.","journal-title":"Intl J Cancer"},{"key":"603_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ejca.2015.10.015","volume":"53","author":"M Nishino","year":"2016","unstructured":"Nishino M, Brais LK, Brooks NV, Hatabu H, Kulke MH, Ramaiya NH. Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach. Eur J Cancer. 2016;53:163\u201370. Available from: doi: https:\/\/doi.org\/10.1016\/j.ejca.2015.10.015.","journal-title":"Eur J Cancer"},{"issue":"4","key":"603_CR11","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/ajco.12571","volume":"12","author":"CT Liu","year":"2016","unstructured":"Liu CT, Chen MH, Chen JS, Chen LT, Shan YS, Lu CH, et al. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: a multi-institution observational study in Taiwan. Asia-Pac J Clncl Oncol. 2016;12(4):396\u2013402. Available from: doi: https:\/\/doi.org\/10.1111\/ajco.12571.","journal-title":"Asia-Pac J Clncl Oncol"},{"issue":"5","key":"603_CR12","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/tri.12275","volume":"27","author":"MC Baas","year":"2014","unstructured":"Baas MC, Struijk GH, Moes D-JAR, van den Berk IAH, Jonkers RE, de Fijter JW, et al. Interstitial pneumonitis caused by everolimus: a case-cohort study in renal transplant recipients. Transpl Int. 2014;27(5):428\u201336. Available from: doi: https:\/\/doi.org\/10.1111\/tri.12275.","journal-title":"Transpl Int"},{"issue":"2","key":"603_CR13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.transproceed.2015.12.039","volume":"48","author":"A Solazzo","year":"2016","unstructured":"Solazzo A, Botta C, Nava F, Baisi A, Bonucchi D, Cappelli G. Interstitial lung disease after Kidney transplantation and the role of everolimus. Transpl Proc. 2016;48(2):349\u201351. Available from: doi: https:\/\/doi.org\/10.1016\/j.transproceed.2015.12.039.","journal-title":"Transpl Proc"},{"issue":"11","key":"603_CR14","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1093\/ndt\/gfm385","volume":"22","author":"S David","year":"2007","unstructured":"David S, K\u00fcmpers P, Shin H, Haller H, Fliser D. Everolimus-associated interstitial pneumonitis in a patient with a heart transplant. Nephrol Dial Transpl. 2007;22(11):3363\u201364. Available from: doi: https:\/\/doi.org\/10.1093\/ndt\/gfm385.","journal-title":"Nephrol Dial Transpl"},{"issue":"7","key":"603_CR15","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.healun.2008.03.016","volume":"27","author":"V Exp\u00f3sito","year":"2008","unstructured":"Exp\u00f3sito V, de Prada JA, G\u00f3mez-Rom\u00e1n JJ, Gonz\u00e1lez-Vilchez F, Llano-Cardenal M, Garc\u00eda-Camarero T, et al. Everolimus-related pulmonary toxicity in heart transplant recipients. The J Heart Lung Transpl. 2008;27(7):797\u2013800. Available from: doi: https:\/\/doi.org\/10.1016\/j.healun.2008.03.016.","journal-title":"The J Heart Lung Transpl"},{"issue":"1","key":"603_CR16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.healun.2008.10.003","volume":"28","author":"J Otton","year":"2009","unstructured":"Otton J, Hayward CS, Keogh AM, Glanville AR, Macdonald PS. Everolimus-associated pneumonitis in 3 heart transplant recipients. The J Heart Lung Transpl. 2009;28(1):104\u201306. Available from: doi: https:\/\/doi.org\/10.1016\/j.healun.2008.10.003.","journal-title":"The J Heart Lung Transpl"},{"key":"603_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.rmed.2017.11.009","volume":"134","author":"M Abe","year":"2018","unstructured":"Abe M, Tsushima K, Ikari J, Kawata N, Terada J, Tanabe N, et al. Evaluation of the clinical characteristics of everolimus-induced lung injury and determination of associated risk factors. Respir Med. 2018;134:6\u201311. Available from: doi: https:\/\/doi.org\/10.1016\/j.rmed.2017.11.009.","journal-title":"Respir Med"},{"issue":"6","key":"603_CR18","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982\u201392. Available from: doi: https:\/\/doi.org\/10.1053\/j.ajkd.2008.12.034.","journal-title":"Am J Kidney Dis"},{"key":"603_CR19","doi-asserted-by":"crossref","unstructured":"Kobayashi J, Kitamura S. KL-6: a serum marker for interstitial pneumonia. Chest. 1995;108(2):311\u201315. Available from: https:\/\/doi.org\/10.1378\/chest.108.2.311. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7634858.","DOI":"10.1378\/chest.108.2.311"},{"issue":"3","key":"603_CR20","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1164\/ajrccm.165.3.2107134","volume":"165","author":"H Ohnishi","year":"2002","unstructured":"Ohnishi H, Yokoyama A, Kondo K, Hamada H, Abe M, Nishimura K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med. 2002;165(3):378\u201381. Available from: doi: https:\/\/doi.org\/10.1164\/ajrccm.165.3.2107134.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"603_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.resinv.2012.02.001","volume":"50","author":"N Ishikawa","year":"2012","unstructured":"Ishikawa N, Hattori N, Yokoyama A, Kohno N. Utility of KL-6\/MUC1 in the clinical management of interstitial lung diseases. Respir Investig. 2012;50(1):3\u201313. Available from: doi: https:\/\/doi.org\/10.1016\/j.resinv.2012.02.001.","journal-title":"Respir Investig"},{"issue":"10","key":"603_CR22","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1136\/thorax.58.10.872","volume":"58","author":"H Ohnishi","year":"2003","unstructured":"Ohnishi H, Yokoyama A, Yasuhara Y, Watanabe A, Naka T, Hamada H, et al. Circulating KL-6 levels in patients with drug induced pneumonitis. Thorax. 2003;58(10):872\u201375. Available from: doi: https:\/\/doi.org\/10.1136\/thorax.58.10.872.","journal-title":"Thorax"},{"issue":"4","key":"603_CR23","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.resinv.2025.04.015","volume":"63","author":"M Yamanaka","year":"2025","unstructured":"Yamanaka M, Ushiki A, Tatsumi K, Gemma A, Hattori N, Tanaka Y, et al. Clinical characteristics of drug-induced interstitial pneumonia in Japan. Respir Investig. 2025;63(4):524\u201331. Available from: doi: https:\/\/doi.org\/10.1016\/j.resinv.2025.04.015.","journal-title":"Respir Investig"},{"issue":"7","key":"603_CR24","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2165\/11532320-000000000-00000","volume":"33","author":"SA Papiris","year":"2010","unstructured":"Papiris SA, Triantafillidou C, Kolilekas L, Markoulaki D, Manali ED. Amiodarone: review of pulmonary effects and toxicity. Drug Saf. 2010;33(7):539\u201358. Available from: doi: https:\/\/doi.org\/10.2165\/11532320-000000000-00000.","journal-title":"Drug Saf"},{"issue":"8","key":"603_CR25","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.nmd.2010.04.008","volume":"20","author":"MC Hermans","year":"2010","unstructured":"Hermans MC, Pinto YM, Merkies IS, de Die-Smulders CE, Crijns HJ, Faber CG. Hereditary muscular dystrophies and the heart. Neuromuscul Disord. 2010;20(8):479\u201392. Available from: doi: https:\/\/doi.org\/10.1016\/j.nmd.2010.04.008.","journal-title":"Neuromuscul Disord"},{"issue":"12","key":"603_CR26","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1093\/ndt\/gfm420","volume":"22","author":"SM Weiner","year":"2007","unstructured":"Weiner SM, Sellin L, Vonend O, Schenker P, Buchner NJ, Flecken M, et al. Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome a single-centre experience and review of the literature. Nephrol Dial Transpl. 2007;22(12):3631\u201337. Available from: doi: https:\/\/doi.org\/10.1093\/ndt\/gfm420.","journal-title":"Nephrol Dial Transpl"},{"key":"603_CR27","doi-asserted-by":"publisher","unstructured":"Bridi GDP, Fonseca E, Kairalla RA, Amaral AF, Baldi BG. Drug-induced lung disease: a narrative review. J Bras Pneumol. 2024;50(4):e20240110. Available from: doi: https:\/\/doi.org\/10.36416\/1806-3756\/e20240110.","DOI":"10.36416\/1806-3756\/e20240110"},{"issue":"7","key":"603_CR28","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1111\/bcp.13591","volume":"84","author":"R Ter Heine","year":"2018","unstructured":"Ter Heine R, van Erp NP, Guchelaar HJ, de Fijter JW, Reinders MEJ, van Herpen CMBurger DM, et al. A pharmacological rationale for improved everolimus dosing in oncology and transplant patients. Brit J Clin Pharma. 2018;84(7):1575\u201386. Available from: doi: https:\/\/doi.org\/10.1111\/bcp.13591.","journal-title":"Brit J Clin Pharma"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-026-00603-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00603-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00603-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:02:11Z","timestamp":1790164931000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40780-026-00603-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["603"],"URL":"https:\/\/doi.org\/10.1186\/s40780-026-00603-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8815683\/v1","asserted-by":"object"}]},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"7 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The institutional ethics review board of the Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, approved the study protocol (approval number: 2529-(13)) and waived the need for written informed consent from each patient. This study was conducted in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"83"}}